CN113874503A - 用于调节crispr活性的系统和方法 - Google Patents

用于调节crispr活性的系统和方法 Download PDF

Info

Publication number
CN113874503A
CN113874503A CN202080024105.4A CN202080024105A CN113874503A CN 113874503 A CN113874503 A CN 113874503A CN 202080024105 A CN202080024105 A CN 202080024105A CN 113874503 A CN113874503 A CN 113874503A
Authority
CN
China
Prior art keywords
polynucleotide
crispr
sequence
nucleotide
cleavable linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080024105.4A
Other languages
English (en)
Chinese (zh)
Inventor
里德·凯尔索
贾里德·卡尔森-斯特弗默
萨希尔·乔什
特拉维斯·毛雷斯
阿纳斯塔西娅·卡迪娜
约翰·安德鲁·沃克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cinseco Co
Original Assignee
Cinseco Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cinseco Co filed Critical Cinseco Co
Publication of CN113874503A publication Critical patent/CN113874503A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080024105.4A 2019-01-25 2020-01-25 用于调节crispr活性的系统和方法 Pending CN113874503A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962797122P 2019-01-25 2019-01-25
US62/797,122 2019-01-25
US201962876177P 2019-07-19 2019-07-19
US62/876,177 2019-07-19
US201962939553P 2019-11-22 2019-11-22
US62/939,553 2019-11-22
PCT/US2020/015127 WO2020154714A2 (en) 2019-01-25 2020-01-25 Systems and methods for modulating crispr activity

Publications (1)

Publication Number Publication Date
CN113874503A true CN113874503A (zh) 2021-12-31

Family

ID=71735803

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080024105.4A Pending CN113874503A (zh) 2019-01-25 2020-01-25 用于调节crispr活性的系统和方法

Country Status (9)

Country Link
US (2) US11884918B2 (https=)
EP (1) EP3914714A4 (https=)
JP (1) JP2022523055A (https=)
KR (1) KR20210123309A (https=)
CN (1) CN113874503A (https=)
AU (1) AU2020210884A1 (https=)
CA (1) CA3127486A1 (https=)
GB (1) GB2597377A (https=)
WO (1) WO2020154714A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114410752A (zh) * 2022-01-24 2022-04-29 华南师范大学 一种基于光控的CRISPR-Cas核酸检测试剂盒及检测方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US20220411790A1 (en) * 2019-10-25 2022-12-29 The Johns Hopkins University A crispr-cas9 platform with an intrinsic off-switch and enhanced specificity
US20240200059A1 (en) * 2021-04-09 2024-06-20 Vor Biopharma Inc. Photocleavable guide rnas and methods of use thereof
US20260103702A1 (en) * 2022-09-30 2026-04-16 Board Of Trustees Of Southern Illinois University Compositions and methods for crispr modulation
WO2024215715A2 (en) * 2023-04-11 2024-10-17 President And Fellows Of Harvard College Chemical ligation techniques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235508A1 (en) * 2011-11-04 2014-08-21 National University Corporation Saitama University Nucleic acid linker
US20180142236A1 (en) * 2015-05-15 2018-05-24 Ge Healthcare Dharmacon, Inc. Synthetic single guide rna for cas9-mediated gene editing
US20180258411A1 (en) * 2015-09-25 2018-09-13 Tarveda Therapeutics, Inc. Compositions and methods for genome editing

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US20090181858A1 (en) * 2004-09-21 2009-07-16 The Scripps Research Institute Adding photoregulated amino acids to the genetic code
BRPI0617191A2 (pt) * 2005-10-12 2011-07-19 Scripps Research Inst modificação pós-traducional de polipeptìdeos expressos em fagos
US8158595B2 (en) 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
CA2689042A1 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
US7923562B2 (en) 2008-06-16 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Photocleavable linker methods and compositions
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
EA201290497A1 (ru) 2009-12-15 2013-01-30 Байнд Байосайенсиз, Инк. Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых
WO2011107747A2 (en) * 2010-03-05 2011-09-09 Medical Research Council Genetically encoded photocontrol
US20130037977A1 (en) 2010-04-08 2013-02-14 Paul A. Burke Preparation of Lipid Nanoparticles
US20120171229A1 (en) 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
CA2824526C (en) 2011-01-11 2020-07-07 Alnylam Pharmaceuticals, Inc. Pegylated lipids and their use for drug delivery
US9228207B2 (en) * 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US10093929B2 (en) * 2013-10-14 2018-10-09 Stc.Unm Modular RNA regulators and methods
US20150376586A1 (en) * 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
WO2016022866A1 (en) 2014-08-07 2016-02-11 Agilent Technologies, Inc. Cis-blocked guide rna
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
WO2016094874A1 (en) * 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
US9650617B2 (en) * 2015-01-28 2017-05-16 Pioneer Hi-Bred International. Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
CN109072224B (zh) * 2016-01-30 2022-07-15 株式会社博纳克 人工单导rna及其用途
US20200291369A1 (en) 2016-03-11 2020-09-17 Erasmus University Medical Center Rotterdam Improved CRISPR-Cas9 Genome Editing Tool
EP3219799A1 (en) * 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
CN109415729B (zh) 2016-04-21 2022-12-09 生命技术公司 具有降低毒性的基因编辑试剂
WO2017217768A1 (ko) * 2016-06-15 2017-12-21 주식회사 툴젠 온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도
EP3638789A4 (en) * 2017-06-12 2021-03-10 California Institute of Technology CONDITIONAL GUIDE RNAS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235508A1 (en) * 2011-11-04 2014-08-21 National University Corporation Saitama University Nucleic acid linker
US20180142236A1 (en) * 2015-05-15 2018-05-24 Ge Healthcare Dharmacon, Inc. Synthetic single guide rna for cas9-mediated gene editing
US20180258411A1 (en) * 2015-09-25 2018-09-13 Tarveda Therapeutics, Inc. Compositions and methods for genome editing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PIYUSH K. JAIN等: "Development of Light-Activated CRISPR Using Guide RNAs with Photocleavable Protectors", ANGEW. CHEM. INT. ED., vol. 55, 24 August 2016 (2016-08-24), pages 1 *
XENIA M. M. WEYEL等: "A Two-Photon-Photocleavable Linker for Triggering Light-Induced Strand Breaks in Oligonucleotides", ACS CHEM. BIOL., vol. 12, 5 July 2017 (2017-07-05), pages 1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114410752A (zh) * 2022-01-24 2022-04-29 华南师范大学 一种基于光控的CRISPR-Cas核酸检测试剂盒及检测方法
CN114410752B (zh) * 2022-01-24 2024-06-25 华南师范大学 一种基于光控的CRISPR-Cas核酸检测试剂盒及检测方法

Also Published As

Publication number Publication date
CA3127486A1 (en) 2020-07-30
US20240209356A1 (en) 2024-06-27
JP2022523055A (ja) 2022-04-21
EP3914714A2 (en) 2021-12-01
KR20210123309A (ko) 2021-10-13
WO2020154714A2 (en) 2020-07-30
US11884918B2 (en) 2024-01-30
GB2597377A (en) 2022-01-26
AU2020210884A1 (en) 2021-08-12
EP3914714A4 (en) 2024-04-10
US20220073912A1 (en) 2022-03-10
GB202110534D0 (en) 2021-09-08
WO2020154714A3 (en) 2020-09-10

Similar Documents

Publication Publication Date Title
CN113874503A (zh) 用于调节crispr活性的系统和方法
CN113677793A (zh) 稳定的crispr复合物
EP4123024B1 (en) Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
JP7093728B2 (ja) 化学的に修飾されたガイドｒｎａを使用する高特異性ゲノム編集
CN109312338B (zh) 治疗单纯疱疹病毒的crispr/cas相关方法及组合物
CN117802102A (zh) 用于治疗β-血红蛋白病的CRISPR/CAS相关方法和组合物
CN112585268A (zh) 通过插入供体多核苷酸用于基因组编辑的组合物和方法
WO2015148860A1 (en) Crispr/cas-related methods and compositions for treating beta-thalassemia
WO2015153791A1 (en) Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
JP2024534945A (ja) 化学修飾を有するプライム編集のためのガイドｒｎａ
JP2024533448A (ja) 化学修飾を有するガイドｒｎａを使用する方法
HK40060726A (en) Systems and methods for modulating crispr activity
HK40060724A (en) Stabilized crispr complexes
US20250302925A1 (en) Conjugated crispr-cas complexes
WO2025061842A1 (en) Gene editing tgm1 mutations for treating autosomal recessive congenital ichthyosis (arci)
HK40029231B (zh) 编码信使核糖核酸(mRNA)的稳定核酸

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060726

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211231

WD01 Invention patent application deemed withdrawn after publication